Neuronal nitric oxide synthase inhibition improves diastolic function and reduces oxidative stress in ovariectomized mRen2.Lewis rats
- PMID: 21293310
- PMCID: PMC3123430
- DOI: 10.1097/gme.0b013e31820390a2
Neuronal nitric oxide synthase inhibition improves diastolic function and reduces oxidative stress in ovariectomized mRen2.Lewis rats
Abstract
Objective: The loss of estrogen in mRen2.Lewis rats leads to an exacerbation of diastolic dysfunction. Because specific neuronal nitric oxide synthase (nNOS) inhibition reverses renal damage in the same model, we assessed the effects of inhibiting neuronal nitric oxide on diastolic function, left ventricular remodeling, and the components of the cardiac nitric oxide system in ovariectomized (OVX) and sham-operated mRen2.Lewis rats treated with N5-(1-imino-3-butenyl)-L-ornithine (L-VNIO; 0.5 mg/kg per day for 28 d) or vehicle (saline).
Methods: Female mRen2.Lewis rats underwent either bilateral oophorectomy (OVX; n = 15) or sham operation (or surgical procedure) (sham; n = 19) at 4 weeks of age. Beginning at 11 weeks of age, the rats were randomized to receive either L-VNIO or vehicle.
Results: The surgical loss of ovarian hormones, particularly estrogen, led to exacerbated hypertension, impaired myocardial relaxation, diminished diastolic compliance, increased perivascular fibrosis, and increased relative wall thickness. The cardiac tetrahydrobiopterin-to-dihydrobiopterin levels were lower among OVX rats compared with sham-operated rats, and this altered cardiac biopterin profile was associated with enhanced myocardial superoxide production and decreased nitric oxide release. L-VNIO decreased myocardial reactive oxygen species production, increased nitrite concentrations, attenuated cardiac remodeling, and improved diastolic function.
Conclusions: Impaired relaxation, diastolic stiffness, and cardiac remodeling were found among OVX mRen2.Lewis rats. A possible mechanism for this unfavorable cardiac phenotype may have resulted from a deficiency in available tetrahydrobiopterin and subsequent increase in nNOS-derived superoxide and reduction in nitric oxide synthase metabolites within the heart. Selective nNOS inhibition with L-VNIO attenuated cardiac superoxide production and limited remodeling, leading to improved diastolic function in OVX mRen2.Lewis rats.
Figures






Similar articles
-
Estrogen therapy, independent of timing, improves cardiac structure and function in oophorectomized mRen2.Lewis rats.Menopause. 2013 Aug;20(8):860-8. doi: 10.1097/GME.0b013e318280589a. Menopause. 2013. PMID: 23481117 Free PMC article.
-
Tetrahydrobiopterin restores diastolic function and attenuates superoxide production in ovariectomized mRen2.Lewis rats.Endocrinology. 2011 Jun;152(6):2428-36. doi: 10.1210/en.2011-0061. Epub 2011 Mar 22. Endocrinology. 2011. PMID: 21427216 Free PMC article.
-
Discoordinate regulation of renal nitric oxide synthase isoforms in ovariectomized mRen2. Lewis rats.Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R819-26. doi: 10.1152/ajpregu.00389.2006. Epub 2006 Oct 5. Am J Physiol Regul Integr Comp Physiol. 2007. PMID: 17023669
-
Role of estrogen in diastolic dysfunction.Am J Physiol Heart Circ Physiol. 2014 Mar 1;306(5):H628-40. doi: 10.1152/ajpheart.00859.2013. Epub 2014 Jan 10. Am J Physiol Heart Circ Physiol. 2014. PMID: 24414072 Free PMC article. Review.
-
Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?Pharmacol Ther. 2013 Dec;140(3):239-57. doi: 10.1016/j.pharmthera.2013.07.004. Epub 2013 Jul 13. Pharmacol Ther. 2013. PMID: 23859953 Review.
Cited by
-
Hypertension after the Menopause: What Can We Learn from Experimental Studies?Physiol Res. 2023 Jul 31;72(Suppl 2):S91-S112. doi: 10.33549/physiolres.935151. Physiol Res. 2023. PMID: 37565415 Free PMC article. Review.
-
Estrogen therapy, independent of timing, improves cardiac structure and function in oophorectomized mRen2.Lewis rats.Menopause. 2013 Aug;20(8):860-8. doi: 10.1097/GME.0b013e318280589a. Menopause. 2013. PMID: 23481117 Free PMC article.
-
Changes in cardiac heparan sulfate proteoglycan expression and streptozotocin-induced diastolic dysfunction in rats.Cardiovasc Diabetol. 2011 Apr 25;10:35. doi: 10.1186/1475-2840-10-35. Cardiovasc Diabetol. 2011. PMID: 21518435 Free PMC article.
-
Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2.Lewis rats.Cardiovasc Res. 2012 Apr 1;94(1):96-104. doi: 10.1093/cvr/cvs090. Epub 2012 Feb 10. Cardiovasc Res. 2012. PMID: 22328091 Free PMC article.
-
The NO/ONOO-cycle as the central cause of heart failure.Int J Mol Sci. 2013 Nov 13;14(11):22274-330. doi: 10.3390/ijms141122274. Int J Mol Sci. 2013. PMID: 24232452 Free PMC article. Review.
References
-
- Lloyd-Jones D, Adams R, Carnethon M, et al. Heart Disease and Stroke Statistics--2009 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21–181. - PubMed
-
- Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9. - PubMed
-
- Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–50. - PubMed
-
- Masoudi FA, Havranek EP, Smith G, et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol. 2003;41:217–23. - PubMed
-
- Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A. Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J. 2006;70(12):1617–23. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R37 HL058091/HL/NHLBI NIH HHS/United States
- K08 AG026764/AG/NIA NIH HHS/United States
- R01 AG033727/AG/NIA NIH HHS/United States
- R01 GM077352/GM/NIGMS NIH HHS/United States
- R01 HL056973/HL/NHLBI NIH HHS/United States
- R29 HL056973/HL/NHLBI NIH HHS/United States
- HL-56973/HL/NHLBI NIH HHS/United States
- R29 HL058091/HL/NHLBI NIH HHS/United States
- R01-AG033727-01/AG/NIA NIH HHS/United States
- R01 HL058091/HL/NHLBI NIH HHS/United States
- HL058091/HL/NHLBI NIH HHS/United States
- K08-AG026764-05/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources